HCA Healthcare (HCA)
NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-07
$423.10+1.45%
Close 2026-07-07 · 1-day change
Reading HCA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HCA free→NYSEHealth CareMedical Care FacilitiesSnapshot 2026-07-07
Reading HCA? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track HCA free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
HCA's growth depends on its recent strong performance and ongoing revenue guidance. Revenue grew 4.3% year over year, and the latest earnings report was inline with expectations. HCA trades at 14× P/E, while the peer median is 21×. This suggests the price reflects less growth than expected. A specific risk is the 19% chance of a miss in the next quarter. Peer multiples imply a price about 50% above where it trades; this read is provisional.
Trailing returns as of 2026-07-07. HCA is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 25 analysts currently covering HCA (as of Jul 2026).
Based on 11 Wall Street analysts offering 12-month price targets for HCA in the last 4 months.
A consensus fair price across 12 valuation methods, at three horizons. Current price $423.10. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Promising study results could enhance growth prospects.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $423.10
The last 12 months of price, then the range of analyst 12-month targets from today’s $423.10.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Price target cut may signal concerns about future performance.
Positive EBITDA projections support revenue growth expectations.
Partnership and expansion could enhance growth trajectory.
Acquisition aligns with growth strategy and expands capabilities.